Brennan Daniel J. 4

4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jun 18, 2026

AI-generated summary of this filing

Updated Jun 18, 2026

Madrigal (MDGL) Director Daniel J. Brennan Receives Equity Awards

What Happened

Daniel J. Brennan, a director of Madrigal Pharmaceuticals, was granted equity awards on 2026-06-17: 404 restricted stock units (RSUs) and 681 derivative awards recorded as an award (no cash paid). Both awards show an acquisition price of $0.00, meaning they were granted as compensation rather than purchased.

Key Details

Transaction date: 2026-06-17; reported on Form 4 filed 2026-06-18 (no late filing indicated).
Awards: 404 RSUs (footnote F1) and 681 derivative awards (footnote F2); both recorded at $0.00.
Vesting: Both awards vest on the earlier of (i) June 17, 2027 or (ii) the issuer’s 2027 annual meeting, provided Brennan remains in service on that date (F1 and F2). F2 specifies the derivative is an option that vests 100% on that schedule.
Shares owned after transaction: not specified in the supplied filing excerpt.
No indication of a 10b5-1 plan, cashless exercise, sale, or tax-withholding event in the provided details.

Context

These were grants/awards (compensation), not open-market purchases or sales. The derivative award appears to be an option that will convert to underlying shares upon vesting; no exercise or sale occurred at grant. Such awards are routine director compensation and reflect future potential ownership contingent on continued service.

Form 4

Period: 2026-06-17

Director

Transactions

Award
Common Stock
[F1]
2026-06-17+404→ 1,371 total
Award
Stock Option (Right to Buy)
[F2]
2026-06-17+681→ 681 total
Exercise: $499.86Exp: 2036-06-17→ Common Stock (681 underlying)

Footnotes (2)

[F1]Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
[F2]The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Signature

/s/ Mardi Dier, as Attorney-in-Fact|2026-06-18

1 file